Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
07 August 2023 - 9:00PM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company that aims to develop the world’s most potent vaccines,
today announced that the company has joined the ctMoniTR Project, a
collaborative research initiative providing foundational evidence
to inform future use of change in circulating tumor DNA (ctDNA) as
an early indicator of long-term clinical benefit from therapeutics
in cancer patients. The ctMoniTR Project is led by Friends of
Cancer Research (Friends).
“ctDNA represents a highly promising biomarker that could
transform the way we develop novel cancer immunotherapies,” said
Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief
Executive Officer of Gritstone bio. “As cancer drug development has
evolved, the field has seen the immense impact that biomarkers can
offer when it comes to identifying effective novel treatments early
on, which can make an enormous difference in the lives of patients.
We’re pleased to serve as a partner on the ctMoniTR Project, which
will help empirically inform the clinical applications where ctDNA
exhibits the greatest potential to accelerate novel drug
development.”
Through the ctMoniTR Project, Gritstone and other partners
contribute data and collaborate with Friends to help develop
data-driven evidence of how ctDNA can inform treatment decisions,
support drug development, and inform regulatory decision-making. To
date, Friends and its partners have collected data from more than
25 studies representing over 3,000 cancer patients, 16 additional
treatments, and several cancer types.
“The use of ctDNA as a tool to predict clinical outcomes with
novel forms of immunotherapy is accelerating at a rapid pace, and
the data emerging from this growing field point to ctDNA
potentially serving as a more precise and accurate predictor of
outcomes than current radiology-based measures,” added Karin Jooss,
Ph.D., Executive Vice President and Head of R&D at Gritstone.
“Through ctMonitor, we aim to help the field better understand and
validate this new, powerful tool. We are thankful to Friends for
their leadership of this unique project and hope our collective
efforts can help bring new therapies to patients safely and
efficiently.”
For more information on the ctMoniTR Project,
visit: https://friendsofcancerresearch.org/ctdna/.
About Gritstone bioGritstone is working to
create the world’s most potent vaccines. We leverage our innovative
vectors and payloads to train multiple arms of the immune system to
attack critical disease targets and have programs in viral diseases
and solid tumors. Independently and with our partners, we are
advancing a portfolio of product candidates with the aim of
improving patient outcomes and eliminating disease.
www.gritstonebio.com
About Friends of Cancer Research Friends
of Cancer Research (Friends) is working to accelerate policy
change, support groundbreaking science, and deliver new therapies
to patients quickly and safely. We unite scientists, pharmaceutical
companies, and policy makers with shared trust and guide them
toward meaningful cooperation. This collaboration among partners
from every healthcare sector ultimately drives advances in science,
policy, and regulation that speed life-saving treatments to
patients. For more information, please
visit https://friendsofcancerresearch.org/
Gritstone Forward-Looking StatementsThis press
release contains forward-looking statements, including, but not
limited to, statements related to our clinical and regulatory
development plans for our product candidates; our expectations
regarding the data to be derived in our ongoing and planned
clinical trials; the timing of commencement of our future
nonclinical studies, clinical trials and research and development
programs; our ability to discover, develop and advance product
candidates into, and successfully complete, clinical trials; and
our plans and strategy regarding maintaining existing and entering
into new collaborations and/or partnerships. Such forward-looking
statements involve substantial risks and uncertainties that could
cause Gritstone’s research and clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the
uncertainties inherent in the drug development process, including
Gritstone’s programs’ clinical stage of development, the process of
designing and conducting preclinical and clinical trials, the
regulatory approval processes, the timing of regulatory filings,
the challenges associated with manufacturing drug products,
Gritstone’s ability to successfully establish, protect and defend
its intellectual property and other matters that could affect the
sufficiency of existing cash to fund operations. Gritstone
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of the company in general, see Gritstone’s
most recent Annual Report on Form 10-K filed on March 9, 2023 and
any subsequent current and periodic reports filed with the
Securities and Exchange Commission.
Gritstone ContactsInvestors:George E.
MacDougallGritstone bio, Inc.ir@gritstone.com
Media:Dan Budwick1AB(973) 271-6085dan@1abmedia.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Apr 2024 to May 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From May 2023 to May 2024